Glenmark Pharma rises as its arm launches Bumetanide Injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Glenmark Pharmaceuticals is currently trading at Rs. 430.80, up by 4.05 points or 0.95% from its previous closing of Rs. 426.75 on the BSE.
The scrip opened at Rs. 427.90 and has touched a high and low of Rs. 430.80 and Rs. 426.80 respectively. So far 1657 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 528.05 on 14-Jan-2022 and a 52 week low of Rs. 348.90 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 440.00 and Rs. 419.30 respectively. The current market cap of the company is Rs. 12041.53 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 34.08% and 19.27% respectively.
Glenmark Pharmaceuticals’ wholly owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.
According to IQVIATM sales data for the 12-month period ending November 2022, the Bumex Injection, 0.25 mg/mL market2 achieved annual sales of approximately $16.5 million.
Glenmark’s current portfolio consists of 179 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
